Slide 1: Investor Presentation
Investor Presentation MAY 2026
Slide 2: Disclaimer
A B O U T G LAU KO S Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on m
Slide 3: WE'LL GO FIRST
A B O U T G LAU KO S WE’LL Solutions Oriented; Creating & GO Exploiting Newest Technologies Unique hybrid pharmaceutical-device company transforming treatment options and quality of life for large and/or underserved patient populations FIRST Innovation is at the core of everything Dropless Therapies
Slide 4: Best-in-Class Growth Company with Industry-Leading Pipeline
A B O U T G LAU KO S Best-in-Class Growth Company with Industry-Leading Pipeline Ocular Hypertension and Open-Angle Glaucoma 30 20+ % 2025 % 10-yr + topline growth revenue CAGR 12 13 Currently Disclosed commercialized pipeline products programs AMD DME 800+ RVO $ Million Invested in R&D since 2018 K
Slide 5: Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities
A B O U T G LAU KO S Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities INTERVENTIONAL INTERVENTIONAL GLAUCOMA KERATOCONUS Radically improves the conventional “drops Fundamentally resets how keratoconus first” care paradigm with standalone is diagnosed, managed and treated to therapies
Slide 6: Major Problem in Glaucoma Care: Non-Compliance with Topical Eye Drops
INTERVENTIONAL GLAUCOMA Major Problem in Glaucoma Care: Non-Compliance with Topical Eye Drops L EG A C Y G L AU CO M A PA R A D I G M N E W I N T E RV E N T I O N A L G L AU CO M A ( I G ) PA R A D I G M MORE TOPICAL MORE SLT FILTRATION PROCEDURAL FILTRATION FILTRATION SLT MIGS MIBS DROPS DROPS (AND
Slide 7: Glaukos is Ideally Positioned to Lead the IG Paradigm Shift
INTERVENTIONAL GLAUCOMA Glaukos is Ideally Positioned to Lead the IG Paradigm Shift IG PARADIGM SLT REFRACTORY PROCEDURAL PHARMACEUTICALS The IG workhorse: Foundational MIGS therapy across the entire disease ADVANCED stage spectrum MIBS MODERATE For patients who have failed FILTRATION SURGERY surgic
Slide 8: iDose TR: Long-Duration Drug Therapy Addresses Patient Non-Compliance
INTERVENTIONAL GLAUCOMA iDose TR: Long-Duration Drug Therapy Addresses Patient Non-Compliance IG PARADIGM SLT 1 PROCEDURAL Anchors securely into scleral tissue for continual elution of unique, highly concentrated travoprost Excellent clinical results PHARMACEUTICALS directly into anterior chamber fu
Slide 9: iDose TR is Just the Beginning
INTERVENTIONAL GLAUCOMA iDose TR is Just the Beginning IG PARADIGM Advancing 6+ future iDose platform products designed to expand SLT iDose utilization and applicability to support future growth, including: PROCEDURAL PHARMACEUTICALS TRIO MIGS • Designed to streamline insertion to help facilitate •
Slide 10: iStent infinite: Best-in-Class MIGS Therapy for Long-Term IOP Control
INTERVENTIONAL GLAUCOMA iStent infinite: Best-in-Class MIGS Therapy for Long-Term IOP Control IG PARADIGM SLT PROCEDURAL PHARMACEUTICALS MIGS 2012 2018 2022 2025 MIBS Pioneered MIGS with Launched Launched Completed enrollment FILTRATION SURGERY iStent approval iStent inject iStent infinite for in iS
Slide 11: IG Represents the Next Wave for Comprehensive Ophthalmology Practices
INTERVENTIONAL GLAUCOMA IG Represents the Next Wave for Comprehensive Ophthalmology Practices A N N UA L U S C ATA R A C T I G PAT I E N T P O P U L AT I O N 2 PROCEDURES1 5M eyes 22M eyes 13M eyes 12M eyes Diagnosed & Treated ~15-20% w/co- Diagnosed morbid glaucoma Prevalence Cataract surgery is: I
Slide 12: IG: A Vision for the Next 10 Years
INTERVENTIONAL GLAUCOMA IG: A Vision for the Next 10 Years By 2035, US ophthalmologists 6 A new breed of IG specialist could emerge, conducting could be performing as 5 primarily injection therapy while vertically integrated ODs and many IG procedures OD referral networks provide preparatory patient
Slide 13: Product Roadmap Underscores Extensive IG Product Depth
INTERVENTIONAL GLAUCOMA Product Roadmap Underscores Extensive IG Product Depth PRODUCT PATIENT STATUS iStent / iStent inject / iStent inject W Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) iStent infinite Glaucoma (failed on prior therapy) FDA Cleared (2022) iStent infinite
Slide 14: Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities
A B O U T G LAU KO S Two Unmet Clinical Needs = Robust Long-Term Growth Opportunities INTERVENTIONAL INTERVENTIONAL GLAUCOMA KERATOCONUS Radically improves the conventional “drops Fundamentally resets how keratoconus first” care paradigm with standalone is diagnosed, managed and treated to therapies
Slide 15: Keratoconus (KC): Debilitating, Sight-Threatening Rare Disease
I N T E R V E N T I O N A L K E R AT O C O N U S Keratoconus (KC): Debilitating, Sight-Threatening Rare Disease • Typical onset in teenage years, most aggressively advancing in patients under age 30 Since 2016 approval, Photrexa has been the • ~90% of cases are bilateral only FDA-approved corneal cr
Slide 16: KC: Vastly Underdiagnosed, Misdiagnosed, Undertreated Disease
I N T E R V E N T I O N A L K E R AT O C O N U S KC: Vastly Underdiagnosed, Misdiagnosed, Undertreated Disease 13 18 Onerous, fragmented journey means only a fraction of patients % 1 ultimately receive sight-saving therapy… of KC patients are diagnosed before age Major Payer 70 Hurdles % of these KC
Slide 17: Transformative Epioxa Therapy Ushers in New Standard of KC Care
I N T E R V E N T I O N A L K E R AT O C O N U S Transformative Epioxa Therapy Ushers in New Standard of KC Care First and only FDA-approved epithelium-on Supplemental oxygen treatment essential for efficiency Incision-free, topical drug therapy catalyzed by oxygen and light Designed to slow or halt
Slide 18: Rare Disease: Significant Investment to Dramatically Improve KC Patient Access
I N T E R V E N T I O N A L K E R AT O C O N U S Rare Disease: Significant Investment to Dramatically Improve KC Patient Access Patient Education OT HE R O PHT HA LMI C RA RE D I SEA SE PHA RMAC E UT I C A LS Specialty Pharma Advocacy Support Engagement Patient Service & Provider Awareness, Market A
Slide 19: Launch Timing for Epioxa & New Rare Disease Infrastructure
I N T E R V E N T I O N A L K E R AT O C O N U S Launch Timing for Epioxa & New Rare Disease Infrastructure Drug availability/launch Go live with patient service and support hub Establish site of care network Establish payer coverage J-Code Effective Date Support advocacy efforts and contracting pro
Slide 20: Next Game-Changing Program: Customized, Spherical Therapy for KC
I N T E R V E N T I O N A L K E R AT O C O N U S Next Game-Changing Program: Customized, Spherical Therapy for KC WHAT IF? CUSTOMIZED, DESI G N E D TO : SPHERICAL Use biomechanical modeling to deliver customized, patterned treatment that Currently in Phase 2 clinical trials THERAPY matches each pati
Slide 21: Product Roadmap for Sustained Leadership in Effective KC Care
I N T E R V E N T I O N A L K E R AT O C O N U S Product Roadmap for Sustained Leadership in Effective KC Care PRODUCT PATIENT STATUS Photrexa (Epi-off) Keratoconus FDA Approved (2016) Epioxa (Epi-on) Keratoconus FDA Approved (2025) iLink 3rd Generation Keratoconus Phase 2 iVeena (IVMED-80) Keratoco
Slide 22: Novel Eyelid Drug Delivery Platform Spearheads Glaukos' Entry into Anterior Segment
i L U T I O N P L AT F O R M Novel Eyelid Drug Delivery Platform Spearheads Glaukos’ Entry into Anterior Segment Part D Pharmaceuticals PLATFORM FOCUS LEAD iLUTION CANDIDATE UPDATE Demodex blepharitis program in Phase 2 clinical stage with patient enrollment advancing Eyelid delivery of potent trans
Slide 23: Biodegradable Implants Designed to Provide Long-Duration Efficacy
R E T I N A X R P L AT F O R M Biodegradable Implants Designed to Provide Long-Duration Efficacy PLATFORM FOCUS LEAD RETINA XR CANDIDATE UPDATE Addressing major drawbacks of conventional retina Patient enrollment is now complete in Phase 2a first-in-human clinical trial of IVT multi- therapies kinas
Slide 24: Disrupting Paradigms with One of the Industry's Most Formidable Portfolios
A B O U T G LAU KO S Disrupting Paradigms with One of the Industry’s Most Formidable Portfolios PRODUCT PATIENT STATUS iStent / iStent inject / iStent inject W Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) iStent infinite Glaucoma (failed on prior therapy) FDA Cleared (2022
Slide 25: Solid Financial Footing Supports Future Pipeline Delivery & Growth Plans
A B O U T G LAU KO S Solid Financial Footing Supports Future Pipeline Delivery & Growth Plans NET SALES1 GLOBAL INFRASTRUCTURE GROSS MARGIN2 84 17 (in millions) (1Q 2026) $627.5 $507 Countries with direct operations % 300+ $383 $315 $283 Global commercial personnel 2022 2023 2024 2025 2026 281 SALES
Slide 26: WE'LL GO FIRST
WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 27: GLAUKOS: Transforming Vision
GLAUKOS TRANSFORMING VISION
Slide 28: Appendix: GAAP to Non-GAAP Reconciliation - 1Q 2026
A B O U T G LAU KO S Appendix GAAP to Non-GAAP Reconciliation - 1Q 2026 (in thousands) 1Q 2026 GAAP Amort. of Dev 1Q 2026 Non-GAAP Gross Margin Tech Intangibles Gross Margin and Developed IP Net Sales $ 150,571 $ 150,571 Cost of Sales $ 33,339 $ (8,675) $ 24,664 Gross Profit $ 117,232 $ 8,675 $ 125,